Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (201-210 of 207) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 207 results.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
Plos Medicine|April 21, 2005
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationRami Kantor, David A Katzenstein, Brad Efron, et al.
The Lancet. HIV|May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trialEsaú C João, R Leavitt Morrison, David E Shapiro, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck, Rami Kantor, Robert W Shafer, et al.
Eclinicalmedicine|April 19, 2021
RBD-specific polyclonal F(ab´)<sub>2</sub> fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trialGustavo Lopardo, Waldo H Belloso, Esteban Nannini, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
The New England Journal of Medicine|November 27, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, et al.
Pageof 21

Showing results (201-210 of 207) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 207 results.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
Plos Medicine|April 21, 2005
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationRami Kantor, David A Katzenstein, Brad Efron, et al.
The Lancet. HIV|May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trialEsaú C João, R Leavitt Morrison, David E Shapiro, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck, Rami Kantor, Robert W Shafer, et al.
Eclinicalmedicine|April 19, 2021
RBD-specific polyclonal F(ab´)<sub>2</sub> fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trialGustavo Lopardo, Waldo H Belloso, Esteban Nannini, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
The New England Journal of Medicine|November 27, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, et al.
Pageof 21